Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Caris Life Sciences Inc banner
C

Caris Life Sciences Inc
NASDAQ:CAI

Watchlist Manager
Caris Life Sciences Inc
NASDAQ:CAI
Watchlist
Price: 16.49 USD -10.72% Market Closed
Market Cap: $4.7B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Gross Profit
Loading...
Operating Income
Loading...
Pre-Tax Income
Loading...
Net Income
Loading...

Wall St Price Targets

CAI Price Targets Summary
Caris Life Sciences Inc

Wall Street analysts forecast CAI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CAI is 28.9 USD with a low forecast of 21.21 USD and a high forecast of 39.9 USD.

CAI Lowest Forecast
21.21 USD
29% Upside
CAI Average Forecast
28.9 USD
75% Upside
CAI Highest Forecast
39.9 USD
142% Upside
Lowest Forecast
Price Target
21.21 USD
29% Upside
Average Forecast
Price Target
28.9 USD
75% Upside
Highest Forecast
Price Target
39.9 USD
142% Upside
Caris Life Sciences Inc Competitors:
Price Targets
CDNA
CareDx Inc
18% Upside
AFYA
Afya Ltd
17% Upside
TELA
TELA Bio Inc
161% Upside
PRQR
ProQR Therapeutics NV
512% Upside
CDNA
CareDx Inc
18% Upside
AFYA
Afya Ltd
17% Upside
TELA
TELA Bio Inc
161% Upside
PRQR
ProQR Therapeutics NV
512% Upside

Revenue
Forecast

97% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
97% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 1 year, the compound annual growth rate for Revenue has been 97%. The projected CAGR for the next 8 years is 15%.

What are analyst estimates?

Gross Profit
Forecast

200% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
200% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Caris Life Sciences Inc

Operating Income
Forecast

N/A
Past Growth
39% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
39% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Operating Income over the next 8 years is 39%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Caris Life Sciences Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

See Also

Summary
CAI intrinsic value, competitors valuation, and company profile.
DCF Valuation
CAI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CAI stock valuation using valuation multiples.
Wall St Estimates
CAI price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CAI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CAI's stock price target?
Price Target
28.9 USD

According to Wall Street analysts, the average 1-year price target for CAI is 28.9 USD with a low forecast of 21.21 USD and a high forecast of 39.9 USD.

What is the Revenue forecast for Caris Life Sciences Inc?
Projected CAGR
15%

Over the last 1 year, the compound annual growth rate for Revenue has been 97%. The projected CAGR for the next 8 years is 15%.

What is the Operating Income forecast for Caris Life Sciences Inc?
Projected CAGR
39%

The compound annual growth rate for Operating Income over the next 8 years is 39%.

Back to Top
ALPHA SPREAD
Follow us
Join 342,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett